Open an account

PMV Pharmaceuticals

PMVP · NASDAQ

$1.39+$0.135 (+10.76%)TodayMarket closed ·
Prev close $1.26

About PMVP

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 54 full-time employees. The company went IPO on 2020-09-25. The firm is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. The company is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.

Employees
54
Headquarters
Princeton, New Jersey
Listed
Sep 25, 2020
Sector
Health Care
Industry
Biotechnology
Website
pmvpharma.com

PMVP key statistics

Market cap
104.96M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
859.77K
Volume
347.59K
Open price
$1.26
High today
$1.41
Low today
$1.26
52 Week high
$1.91
52 Week low
$1.02

PMV Pharmaceuticals (PMVP) at a glance

PMV Pharmaceuticals (PMVP) last traded at $1.39, with a market cap of 104.96M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.26 and $1.41. The current price is 10.3% above the day's low and 1.4% below its high.

Volume so far is 347.59K shares, below the average of 859.77K shares a day.

Over the past year PMV Pharmaceuticals has ranged from $1.02 to $1.91, and now sits 42% of the way up that range.

PMV Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.34 per share against an estimate of -$0.3953.

The average analyst price target is $4.28, 208.2% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $4.28
Low
$3.03
Now
$1.39
High
$5.25

PMVP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 12.8% on average.

  1. Q3 FY24: reported -$0.37 per share against an estimate of -$0.358
  2. Q4 FY24: reported -$0.45 per share against an estimate of -$0.3882
  3. Q1 FY25: reported -$0.34 per share against an estimate of -$0.3819
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.391
  5. Q3 FY25: reported -$0.40 per share against an estimate of -$0.4106
  6. Q4 FY25: reported -$0.34 per share against an estimate of -$0.4131
  7. Q1 FY26: reported -$0.34 per share against an estimate of -$0.4182
  8. Q2 FY26: reported -$0.34 per share against an estimate of -$0.3953

PMVP news

  • Vandana Singh

    PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Vandana Singh

    Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

Similar companies

Companies in the same industry as PMV Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.